Cam­bridge spin­out grabs $23M round to launch a new cam­paign to tack­le pro­tein mis­fold­ing

A spin­out biotech with sci­en­tif­ic roots that ex­tend in­to the Uni­ver­si­ty of Cam­bridge and Lund Uni­ver­si­ty has just raised a $23 mil­lion A round aimed at a com­mon tar­get in drug de­vel­op­ment cir­cles: mis­fold­ed pro­teins.

Fold­ing mal­func­tions are be­hind a long ros­ter of tough dis­eases, but have so far re­sist­ed ef­forts at re­solv­ing them in a way that can pre­vent dis­eases. Wren Ther­a­peu­tics, based in Cam­bridge, UK, says the se­cret to this sauce lies in un­der­stand­ing the “chem­i­cal ki­net­ics” be­hind mis­fold­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.